Janssen Submits Marketing Authorisation Application to EMA S

The submission to the European Medicines Agency is based on results from the Phase 3 MAGNITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisonefor the treatment of

Related Keywords

Japan , United States , American , Laura Coughlan , Gerhardt Attard , Kiran Patel , Mathai Mammen , Zejula Sm , Janssen Biotech Inc , Tesaro Inc , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Janssen Cilag International , International Agency For Research On Cancer , European Union , Clinical Development , None Of The Janssen Pharmaceutical Companies , World Health Organization , European Commission , Exchange Commission , Companies Of Johnson , European Medicines Agency , Johnson , Marketing Authorisation Application , Professor Gerhardt , Primary Study Investigator , Clinician Scientist , Team Leader , University College London Cancer , American Society , Clinical Oncology Genitourinary Cancers Symposium , Annual Meeting , Vice President , Solid Tumors , Executive Vice President , Janssen Biotech , Metastatic Castration Resistant Prostate Cancer , Pharmaceutical Companies , Cardiovascular Metabolism , Infectious Diseases Vaccines , Research Development , Concerning Forward Looking Statements , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Ataxia Telangiectasia , Checkpoint Kinase , Histone Deacetylase , Last Accessed April , Combination With Abiraterone Acetate , Prednisone Versus Abiraterone Acetate , Participants With Deleterious Germline , Somatic Homologous Recombination Repair , Prostate Cancer , Prevalence Worldwide , Del Pozo , Prospective Cohort Study , Janssen , Ubmits , Marketing , Authorisation , Application , Seeking , Approval , Niraparib , Abiraterone , Acetate , Ual , Action , Tablet , Plus , Prednisone , Treatment , Patients , Gene , Mutated , Metastatic , Castration ,